Pasithea Therapeutics (KTTA) Operating Expenses (2021 - 2026)
Pasithea Therapeutics (KTTA) posted Operating Expenses of $4.9 million for Q1 2026, down 68.43% sequentially from $15.4 million in Q4 2025, and up 32.49% YoY from $3.7 million in Q1 2025.
Pasithea Therapeutics (KTTA) Operating Expenses (2021 - 2026) Analysis & Trends
Pasithea Therapeutics has reported Operating Expenses for 6 years, with the latest figure at $4.9 million in Q1 2026.
- Quarterly Operating Expenses rose 32.49% year-over-year to $4.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $25.1 million (up 28.41% YoY) and the FY2025 annual result came in at $20.9 million, up 46.37% from the prior year.
- Operating Expenses fell to $4.9 million in Q1 2026 per KTTA's latest filing, from $15.4 million in the prior quarter.
- Over five years, Operating Expenses peaked at $15.4 million in Q4 2025 and troughed at $432832.0 in Q2 2022.
- A 5-year average of $4.6 million and a median of $3.8 million in 2023 frame the typical range for Operating Expenses.
- The sharpest annual moves came in 2023 and 2025: Operating Expenses jumped 784.57% in 2023, then plunged 56.77% in 2025.
- Over 5 years, Operating Expenses stood at $5.3 million in 2022, then retreated by 3.27% to $5.1 million in 2023, then soared by 73.79% to $8.9 million in 2024, then soared by 72.66% to $15.4 million in 2025, then slumped by 68.43% to $4.9 million in 2026.
- According to Business Quant data, Operating Expenses over the past three periods registered $4.9 million, $15.4 million, and $3.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Opex (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 2.09 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 3.00 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 2.89 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 960.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 1.21 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 1.06 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 427.03 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 541.02 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -784.57 Mn |
| 10 | Pasithea Therapeutics | 15.13 Mn | 15.13 Mn | - | 5.71 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 4.88 Mn |
| Dec 31, 2025 | 15.45 Mn |
| Sep 30, 2025 | 3.11 Mn |
| Jun 30, 2025 | 1.71 Mn |
| Mar 31, 2025 | 3.68 Mn |
| Dec 31, 2024 | 8.95 Mn |
| Sep 30, 2024 | 3.00 Mn |
| Jun 30, 2024 | 3.95 Mn |
| Mar 31, 2024 | 4.04 Mn |
| Dec 31, 2023 | 5.15 Mn |
| Sep 30, 2023 | 3.79 Mn |
| Jun 30, 2023 | 3.83 Mn |
| Mar 31, 2023 | 3.21 Mn |
| Dec 31, 2022 | 5.32 Mn |
| Sep 30, 2022 | 4.38 Mn |
| Jun 30, 2022 | 432,832.00 |
| Mar 31, 2022 | 2.73 Mn |
| Dec 31, 2021 | 1.95 Mn |
| Sep 30, 2021 | 1.27 Mn |
| Jun 30, 2021 | 727,947.00 |